

1 **Oligosymptomatic long-term carriers of SARS-CoV-2 display impaired innate**  
2 **resistance and high Spike-specific neutralizing antibodies**

3  
4 **Authors:** Elena Montes-Cobos <sup>1</sup>, Victoria C Bastos <sup>1,4</sup>, Clarice Monteiro <sup>1</sup>, João CR de Freitas <sup>1</sup>,  
5 Heiny DP Fernandes <sup>1</sup>, Clarice S Constancio <sup>2</sup>, Danielle AS Rodrigues <sup>3</sup>, Andreza MDS Gama <sup>1</sup>,  
6 Vinicius M Vidal <sup>1</sup>, Leticia S Alves <sup>1</sup>, Laura Zalcborg-Renault <sup>1,4</sup>, Guilherme S de Lira <sup>1,4</sup>, Victor  
7 A Ota <sup>1,4</sup>, Carolina Caloba <sup>6</sup>, Luciana Conde <sup>3</sup>, Isabela C Leitão <sup>4</sup>, Amilcar Tanuri <sup>5</sup>, Orlando DC  
8 Ferreira <sup>5</sup>, Renata M Pereira <sup>6</sup>, André M Vale <sup>3</sup>, Terezinha M Castiñeiras <sup>4</sup>, Dominique Kaiserlian  
9 <sup>7,†</sup>, Juliana Echevarria-Lima <sup>2,†</sup>, Marcelo T Bozza <sup>1,†,\*</sup>.

10

11 **Affiliations:**

12 <sup>1</sup> Laboratório de Inflamação e Imunidade, Instituto de Microbiologia Paulo de Góes, Universidade  
13 Federal do Rio de Janeiro, Rio de Janeiro, Brazil.

14 <sup>2</sup> Laboratório de Imunologia Básica e Aplicada, Instituto de Microbiologia Paulo de Góes,  
15 Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.

16 <sup>3</sup> Laboratório de Biologia de Linfócitos, Instituto de Biofísica Carlos Chagas Filho, Universidade  
17 Federal do Rio de Janeiro, Rio de Janeiro, Brazil

18 <sup>4</sup> Departamento de Doenças Infecciosas e Parasitárias, Faculdade de Medicina, Universidade  
19 Federal do Rio de Janeiro, Rio de Janeiro, Brazil

20 <sup>5</sup> Laboratório de Virologia Molecular, Instituto de Biologia, Universidade Federal do Rio de  
21 Janeiro, Rio de Janeiro, Brazil

22 <sup>6</sup> Laboratório de Imunologia Molecular, Instituto de Microbiologia Paulo de Góes, Universidade  
23 Federal do Rio de Janeiro, Rio de Janeiro, Brazil

24 <sup>7</sup> Mucosal Immunity Vaccination & Biotherapies Laboratory, INSERM U1060, Université Claude  
25 Bernard Lyon 1, Centre hospitalier Lyon-Sud, Pierre-Benite, France

26

27 \* Corresponding authors: [mbozza@micro.ufrj.br](mailto:mbozza@micro.ufrj.br).

28 † Contributed equally to the conceptualization of the work

29

30 **Summary:** The vast spectrum of clinical features of COVID-19 keeps challenging scientists and  
31 clinicians. Control of pathogen load (host resistance) and prevention of tissue damage (disease  
32 tolerance) are essential for the outcome of infectious diseases. Both low resistance and high disease  
33 tolerance might result in long-term viral persistence, but the underlying mechanisms remain  
34 unclear. Here, we studied the immune response of immunocompetent COVID-19 patients with  
35 prolonged SARS-CoV-2 infection by immunophenotyping, cytokine and serological analysis.  
36 Despite viral loads and symptoms comparable to regular mildly-symptomatic patients, long-term  
37 carriers displayed weaker systemic IFN-I responses and fewer circulating pDCs and NK cells at  
38 disease onset. Type 1 cytokines remained low, while type-3 cytokines were in turn enhanced.  
39 Interestingly, the plasma of these patients showed a higher spike-specific neutralization capacity.  
40 The identification of very early distinct immune responses in long-term carriers adds up to our  
41 understanding on essential host protective mechanisms to ensure tissue damage control despite  
42 prolonged viral infection.

43

44 **Key words:** SARS-CoV-2, host resistance, disease tolerance, persistent infection, IFN-I, Type 1/3  
45 immunity, neutralizing antibodies.

46

## 47 INTRODUCTION

48 Patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)  
49 have clinical presentations ranging from asymptomatic-mildly symptomatic (70-90%) to severe  
50 and critical (10-30%)<sup>1-4</sup> . These different clinical outcomes, including the risk of COVID-19-  
51 related death, have been associated with age, gender, and underlying comorbidities, such as obesity  
52 and diabetes<sup>2,5,6</sup>. Hospitalized patients with severe COVID-19 present an increase in inflammatory  
53 cytokines, monocytes and neutrophils, and a marked decrease in lymphocytes compared to patients  
54 with mild disease<sup>7-9</sup>. Moreover, a significant fraction of patients with life-threatening COVID-19  
55 present defects in type I IFNs (IFN-I) due to inborn mutations and auto-antibodies, pointing to a  
56 critical role of IFN-I in the immune response against SARS-CoV-2<sup>10-12</sup>. These distinct immune  
57 and inflammatory signatures are observed early after COVID-19 diagnosis, correlate with  
58 divergent disease trajectories and might have prognostic value<sup>9,13,14</sup> .

59 The interplay of resistance to limit pathogen burden and maintenance of tissue homeostasis,  
60 also known as disease tolerance, is central to host and pathogen interactions and determines disease  
61 progression and outcome<sup>15,16</sup>. Whilst resistance represents the ability to contain pathogen  
62 replication and spread in the host, disease tolerance reflects the capacity to limit deleterious effects  
63 of infectious agents and the associated inflammatory response. Indeed, critically ill COVID-19  
64 patients present local and systemic inflammation with severe tissue dysfunction regardless of  
65 pathogen loads<sup>9,13,14</sup>. Alternatively, immunosuppressed individuals, who exemplify the paradigm  
66 of low host resistance, display a variety of clinical presentations, from asymptomatic to severe<sup>17-</sup>  
67<sup>20</sup>. These observations suggest that disease tolerance mechanisms controlling tissue homeostasis  
68 might underly a benign clinical course of SARS-CoV-2 infection and determine the fitness of  
69 COVID-19 patients<sup>21</sup>.

70 Low resistance might impact SARS-CoV-2 clearance in multiple ways, leading to high viral titers  
71 in the upper-respiratory tract (URT), dissemination to other tissues, especially the lungs, or long-  
72 term virus persistence. Although viral persistence has been more frequently described in  
73 immunosuppressed patients, persistent URT infection and long-term virus shedding have been  
74 documented in immunocompetent patients with asymptomatic or mild COVID-19 as well <sup>22-26</sup>.  
75 Most long-term carriers remained SARS-CoV-2 positive by qRT-PCR despite seroconversion,  
76 reinforcing the risk of continuous SARS-CoV-2 transmission <sup>23,27,28</sup>. Defects in antigen-specific  
77 cytotoxic T cell responses were found in such patients <sup>29</sup>, but the immune dynamics during the first  
78 days of infection remains unclear. Thus, the aim of this study is to gain insights into the immune  
79 mechanisms associated to prolonged SARS-CoV-2 infection in oligosymptomatic,  
80 immunocompetent subjects. First, we identified early pathophysiological immune markers that  
81 may predict COVID-19 progression. Overall, our study reveals alternative immune strategies to  
82 cope with SARS-CoV-2 infection, shedding light on the mechanisms of resistance and disease  
83 tolerance in COVID-19.

84

85

## 86 **RESULTS**

### 87 **Demographic characterization of study cohort**

88 Our study cohort is composed of individuals tested for SARS-CoV-2 infection at the  
89 Diagnostic Screening Center for COVID-19 of the Federal University of Rio de Janeiro (CTD-  
90 UFRJ) from April to December 2020. Weekly follow-up was offered to those subjects who tested  
91 positive for the presence of SARS-CoV-2 RNA by quantitative PCR with reverse transcription  
92 (RT-qPCR) in nasopharyngeal swab samples, until SARS-CoV-2 RNA was no longer detectable.

93 Initial studies performed in the CTD-UFRJ cohort found a median of SARS-CoV-2 RT-qPCR  
94 positivity around three weeks after symptoms onset<sup>22</sup>. Day 21 after symptom onset (DSSO) was  
95 thus used as a putative threshold time point of viral clearance from the URT. From those  
96 individuals who volunteered to longitudinal follow-up testing, we selected 33 patients with  
97 persistent SARS-CoV-2 infection (P), representing long-term carriers, defined by detectable  
98 SARS-CoV-2 RNA (i.e. Ct < 38) at  $\geq 21$  DSSO. Thirty-two SARS-CoV-2 infected patients with  
99 a negative RT-qPCR (i.e. Ct  $\geq 38$ ) at  $\leq 21$  DSSO were also included as COVID-19 control study  
100 group, thereafter referred to as non-persistent (NP), and 24 age- and gender-matched  
101 asymptomatic, non-infected individuals (confirmed by the absence of spike-specific IgM and IgG  
102 in the plasma) were selected as the reference group (NI) (Fig. 1A). The proportion of men and  
103 women was equally distributed among the study groups. The median age distribution was 36  
104 ( $\pm 9.67$ ) years of age for the NI group, 36 ( $\pm 11.05$ ) for the those of the NP group and 38 ( $\pm 12.13$ )  
105 for patients with persistent SARS-CoV-2 infection (P). COVID-19 patients included in this study  
106 were either oligosymptomatic, presenting mild symptoms including fever, headache, cough,  
107 sneeze, anosmia or myalgia, or asymptomatic at the time of enrollment. Despite prolonged URT  
108 infection, long term carriers displayed neither a significantly longer duration of symptoms (Fig.  
109 1B) nor augmented disease severity markers in the plasma (Fig. 1C). None of the patients of our  
110 cohort developed severe COVID-19 requiring hospitalization or oxygen therapy. The most  
111 common comorbidities reported by the patients were hypertension (15.63% of NP versus 27.28%  
112 of P), hypothyroidism (6.25% NP versus 12.12% of P), and diabetes mellitus (6.25% of NP versus  
113 3.03% of P) (Table 1).

114

115 **Table 1. Demographics of patient cohort**

116

117

	Non persistent ( <i>n</i> =32)	Persistent ( <i>n</i> =33)	<i>P</i> value
<b><i>Characteristics</i></b>			
Age, median (years)	36 ( $\pm$ 11.05)	38 ( $\pm$ 12.13)	0.4606
Sex, female	16/32 (50%)	17/33 (51.52%)	
Last positive, median (DSSO)	5 ( $\pm$ 3.2)	31 ( $\pm$ 21.5)	<0.0001
<b><i>Comorbidities</i></b>			
Hypertension	5/32 (15.63%)	9/33 (27.28%)	
Diabetes Mellitus	2/32 (6.25%)	1/33 (3.03%)	
Hypothyroidism	2/32 (6.25%)	4/33 (12.12%)	
Others	4/32 (12.50%)	5/33 (15.16%)	

118

119

120 **SARS-CoV-2 persistency does not depend on viral load or mucosal cytokines**


121 As SARS-CoV-2 enters the organism via the URT, early local immunity at the  
122 nasopharyngeal mucosa may be important for fast and efficient viral clearance. Therefore, we first  
123 analyzed early viral loads and immune parameters in the nasopharyngeal mucosa of patients that  
124 eventually developed prolonged SARS-CoV-2 infection. Viral titers, determined by qRT-PCR, in  
125 nasopharyngeal swabs of long-term carriers were similar to those of non-persistent COVID-19  
126 patients during the first days of infection ( $\leq 7$  DSSO). Long-term carriers presented detectable  
127 viral RNA in the URT for up to 4 weeks, albeit with slightly higher Ct values (Fig. 1D). Strikingly,  
128 a group of patients still tested positive by RT-qPCR for longer than 8 weeks, with the latest  
129 positivity result being at 134 DSSO in one patient (Fig. 1E).

130 Next, we used a multiplex assay to compare a set of 47 immune mediators, including IFN $\alpha$ ,  
131 IL29, IFN $\gamma$ , IL-1 $\beta$ , IL-4, IL-13, IL-17A and IL-10, in nasopharyngeal swab samples collected at  $\leq$   
132 10 DSSO from a group of non-persistent patients (NP, *n*=9) and long-term carriers (P, *n*=13). The  
133 results did not show any differences in early cytokines between both groups (Fig. 1F, Suppl. Fig.

134 1A). These results suggest that early alterations of these mucosal cytokines at the entry site of  
135 SARS-CoV-2 do not drive viral persistence.

136

137 **Fig 1.**



138

139

140 **Figure 1. Overview of clinical features, viral loads, and mucosal immunity parameters of**

141 **COVID-19 patients. (A) SARS-CoV-2 positivity by qRT-PCR in nasopharyngeal samples, sex**



142 and age of non-infected controls (NI), non-persistent (NP) and persistent (P) COVID-19 patients.  
143 (B) Duration of symptoms of NP and P patients, represented as days after symptom onset (DSSO).  
144 (C) Quantification of the plasma damage markers D-dimer and Ferritin in NI ( $n=14$ ), NP ( $n=26$ ),  
145 and P ( $n=24$ ) at  $<10$  DSSO by multiplex magnetic bead-based immunoassay. (D) Cycle threshold  
146 (Ct) values of qRT-PCR for SARS-CoV-2 target genes from nasopharyngeal samples from NP  
147 ( $n=32$ ) and P ( $n=33$ ) patients by DSSO. (E) SARS-CoV-2 positivity of NP ( $n=32$ ) and P ( $n=33$ )  
148 patients by DSSO. (F) Quantification of IFN $\alpha$ , IL-29, IFN $\gamma$ , IL-1b, IL-4, IL-13, IL-17, and IL-10  
149 from URT samples in NP ( $n=9$ ) and P ( $n=13$ ) at  $<10$  DSSO by multiplex immunoassay. Each dot  
150 represents a subject. Filled dots represent a positive qRT-PCR of nasopharyngeal samples for  
151 SARS-CoV-2, while empty dots represent a negative qRT-PCR. DSSO, Days since symptom  
152 onset.

153

154

### 155 **Long-term carriers present reduced systemic type I IFN responses**

156 Early dysregulated systemic inflammatory and antiviral responses have been pointed out  
157 as potential drivers of distinct clinical progression of COVID-19<sup>9,10,13</sup>. To gain insights into  
158 specific immune mechanisms leading to prolonged SARS-CoV-2 infection, we analyzed innate  
159 immune cells and soluble mediators in non-infected individuals, non-persistent COVID-19  
160 patients, and long-term carriers early after disease onset ( $\leq 10$  DSSO). Long-term carriers  
161 displayed a different distribution pattern of circulating monocyte populations, characterized by a  
162 drop in the frequency of classical ( $\text{lin}^- \text{CD14}^+ \text{CD16}^-$ ) monocytes and a modest increase in the  
163 percentage of non-classical ( $\text{lin}^- \text{CD14}^- \text{CD16}^+$ ) monocytes (Fig. 2A). Additionally, we found a  
164 significant reduction of pDC frequencies ( $\text{lin}^- \text{CD14}^- \text{CD304}^+$ ) in the blood of these patients (Fig.


165 2B), which may be due to lower numbers of circulating pDCs or to higher tissue recruitment.  
166 Nonetheless, we detected augmented expression of HLA-DR on this cell population, indicative of  
167 a more mature phenotype and a predisposition to apoptosis<sup>30</sup>. Other monocyte and dendritic cell  
168 populations did not vary between both groups of patients (Suppl. Fig. 3A).

169 Since pDCs are the first and major IFN-I producers during viral infections<sup>31,32</sup>, it was not  
170 unexpected that plasma concentrations of IFN $\alpha$  and IP-10 (CXCL10) in long-term carriers did not  
171 increase as much as in non-persistent patients (Fig. 2C). Expression analysis of the interferon-  
172 inducible genes (ISGs) IRF7 and ISG-15 in PBMCs also showed reduced induction of both genes  
173 in patients from the P group compared to those of the NP group (Fig. 2D). No differences were  
174 observed in the plasma concentrations of IFN $\lambda$  (IL-29) (Fig. 2C), IFN $\beta$  or IFN $\omega$  (Suppl. Fig. 3B),  
175 nor in the occurrence of anti-IFN $\alpha$ 2 autoantibodies (Fig. 2 E). Neither did we find changes in most  
176 of the inflammatory mediators predictive of poor outcome in COVID-19, such as TNF $\alpha$ , MCP-1  
177 (CCL2), IL1 $\beta$ , IL-6 or IL-1 RA (Fig. 2F, Suppl. Fig. 3B)<sup>7-9</sup>. Only plasma concentrations of the  
178 regulatory cytokine IL-10 were lower in long-term carriers than in non-persistent patients.

179 Furthermore, we titrated plasma levels of molecules involved in tissue damage and repair  
180 at disease onset, some of which have been previously connected to disease tolerance<sup>33</sup>. In contrast  
181 to non-persistent patients, long-term carriers showed no increase in tissue growth factors like  
182 PDGF-BB, basic FGF and VEGF, indicating that systemic tissue repair mechanisms were not  
183 induced in these patients (Fig. 2F). Syndecan-1, involved in modulation of inflammation and tissue  
184 repair and a hallmark of endothelial damage<sup>34</sup>, was comparable in all groups. Collectively, our  
185 results show altered innate immune responses, a weaker antiviral state and limited induction of  
186 tissue repair during the first days of prolonged SARS-CoV-2 infection.

187

188 **Fig. 2**



189

190

191 **Figure 2. Early innate immune profiles distinguish between persistent and non-persistent**  
192 **patients.** Immunophenotyping of innate immune cell populations in PBMC from NI ( $n=15$ ), NP  
193 ( $n=22$ ) and P ( $n=27$ ) at  $<10$  DSSO, depicting (A) LIVE/DEAD<sup>+</sup>CD3<sup>-</sup>CD19<sup>-</sup>CD56<sup>-</sup> (lin<sup>-</sup>)  
194 CD14<sup>+</sup>CD16<sup>-</sup> classical monocytes (cMono), CD14<sup>+</sup>CD16<sup>+</sup> intermediate monocytes (iMono),  
195 CD14<sup>-</sup>CD16<sup>+</sup> non-classical monocytes (ncMono), (B) lin<sup>-</sup>CD14<sup>-</sup>CD16<sup>-</sup>CD304<sup>+</sup> plasmacytoid cells  
196 (pDC) and activated pDCs (MFI of HLA-DR in pDC). Quantification of plasma cytokines in NI  
197 ( $n=17$ ), NP ( $n=27$ ) and P ( $n=32$ ) at  $<10$  DSSO by multiplex magnetic bead-based immunoassay.  
198 (D) Expression of IRF-7 and ISG-15 in PBMC of NP and P at  $< 10$  DSSO by PCR. Each dot  
199 represents a different subject. Statistical significance was calculated using Mann-Whitney test or  
200 Kruskal-Wallis analysis followed by Dunn post-test and indicated by \* $p < 0.05$ ; \*\* $p < 0.01$ ; and  
201 \*\*\* $p < 0.001$ . DSSO, Days since symptom onset.

202

203


## 204 **Type 1 responses shift to type 3 immunity in long-term carriers**

205 The immune system orchestrates distinct resistance mechanisms depending on the nature  
206 of the infectious agent, the site of infection and the time after infection onset. Type 1 immunity,  
207 mediated by IFN $\gamma$ , NK cells, T helper 1 (Th1) lymphocytes and cytotoxic T cells, is primarily  
208 induced in response to intracellular pathogens, such as viruses. We thus analyzed type 1 immune  
209 responses in our cohort of long-term carriers. First, we detected lower frequencies of circulating  
210 NK cells in persistently-infected COVID-19 patients compared to non-persistent ones (Fig. 3A).  
211 We also observed that the proportion of circulating naïve CD4<sup>+</sup> was slightly reduced in patients of  
212 the P group (Fig. 3B). These immunophenotypic alterations were in line with a drop in plasmatic  
213 IL-7 (Fig. 3C), as this cytokine contributes to NK cell and naïve/memory T cell development and

214 survival<sup>35</sup>. Additionally, we stimulated total PBMCs *in vitro* with anti-CD3/CD28 beads in order  
215 to analyze the inducible cytokine production by circulating CD4<sup>+</sup> and CD8<sup>+</sup> T cells. Polyclonally-  
216 activated PBMCs from long-term carriers showed elevated amounts of TNF $\alpha$  produced by T helper  
217 cells and Granzyme B by cytotoxic T cells, while the synthesis of these cytokines in the non-  
218 persistent COVID-19 patients was not different from that of non-infected individuals at this early  
219 time point ( $\leq 10$  DSSO) (Fig. 3D). Further analysis of systemic hallmarks of type 1 immunity  
220 revealed significantly lower IFN $\gamma$  and IL-12 concentrations in the plasma of long-term carriers  
221 (Fig. 3E), but higher circulating levels of IL-15, a broadly pleiotropic cytokine with stimulating  
222 effects on NK cells and T lymphocytes.

223         Considering the reduced type 1 immunity taking place only in the of patients subsequently  
224 evolving towards a persistent infection, we next explored whether long-term carriers presented a  
225 functional deviation to type 2 or type 3 immunity. Analysis of plasma cytokines showed that, while  
226 type 2-associated cytokines, such as IL-4, IL-13 and IL-9, were poorly represented in the plasma  
227 of patients with prolonged infection, the concentration of IL-17A was strongly increased (Fig. 3F,  
228 G). Soluble mediators responsible for neutrophil development and recruitment, such as G-CSF,  
229 MIP-1 $\alpha$  (CCL4) and IL-8 (CXCL8) were also augmented, indicating a more prominent type 3  
230 immune profile. These observations suggest a shift from type 1 immunity to type 3 immune  
231 responses in patients with persistent SARS-CoV-2 infection.

232 **Fig. 3**



234 **Figure 3. Dampened type 1 immunity in persistent patients.** Immunophenotyping of immune  
235 cell populations in PBMC from NI ( $n=15$ ), NP ( $n=22$ ) and P ( $n=27$ ) at <10 DSSO depicting (A)  
236 CD3<sup>-</sup>CD56<sup>+</sup> natural killer cells (NK cells), (B) CD19<sup>-</sup>CD3<sup>+</sup> T lymphocytes (CD3),  
237 CD4<sup>+</sup>CD27<sup>+</sup>CD45RA<sup>+</sup> naive CD4 T lymphocytes (Naive CD4), and CD8<sup>+</sup>CD27<sup>+</sup>CD45RA<sup>+</sup> naive  
238 CD8 T lymphocytes (Naive CD8). (C) Quantification of plasma IL-7 in ( $n=17$ ), NP ( $n=27$ ) and P  
239 ( $n=32$ ) at <10 DSSO by multiplex magnetic bead-based immunoassay. (D) Frequencies of CD4<sup>+</sup>  
240 T lymphocytes producing IFN $\gamma$ , TNF $\alpha$  and IL-6 and CD8<sup>+</sup> T lymphocytes producing IFN $\gamma$ , TNF $\alpha$   
241 and Granzyme B (Grz B) after polyclonal in vitro stimulation with anti-CD3/CD28 beads of  
242 PBMCs from ( $n=12$ ), NP ( $n=11$ ) and P ( $n=23$ ). Quantification of plasma (E) IFN $\gamma$ , IL-12, IL-15,  
243 (F) IL-4, IL-13, IL-9, (G) IL-17A, G-CSF, MIP-1 $\alpha$ , and IL-8 in ( $n=17$ ), NP ( $n=27$ ) and P ( $n=32$ )  
244 at <10 DSSO by multiplex magnetic bead-based immunoassay. Statistical significance was  
245 calculated using Mann-Whitney test or Kruskal-Wallis analysis followed by Dunn post-test and  
246 indicated by \* $p$  % 0.05; \*\* $p$  % 0.01; and \*\*\* $p$  % 0.001. DSSO, Days since symptom onset.

247

248

### 249 **Patients developing persistent infection display an early distinct immune signature**




250 Unsupervised cluster analysis of plasma cytokines at  $\leq 10$  DSSO revealed at least two  
251 groups of immune mediators that were differentially regulated in patients with normal resolution  
252 of infection compared to those with long-term infection (Fig. 4A). Cluster 1, composed of IL-6,  
253 IL-8, IL-17A, G-CSF, IL-15 and MIP-1 $\alpha$ , was overrepresented in most long-term carriers, whereas  
254 the cytokines from cluster 5, containing IL-9, IL-10, IFN $\gamma$  and IL-12, were reduced. Additionally,  
255 we combined plasma cytokine data with immunophenotyping data from the same time points (Fig  
256 4B and Suppl. Fig.4A, B). The correlation matrix of soluble proteins and immune cell subtypes

257 revealed a positive correlation of effector CD8<sup>+</sup> T cells with Th1 and Th2 cytokines, which, in  
258 turn, inversely correlated with the activation of alternative monocytes and pDCs (Fig. 4B).  
259 Furthermore, unsupervised cluster analysis on cytokine data by t-Distributed Stochastic Neighbor  
260 Embedding (t-SNE) identified four different groups of patients (Suppl. Fig. 4B). All non-infected  
261 controls gathered in one cluster, whereas long-term carriers were distributed in three different  
262 groups along with non-persistent patients, irrespective of age, gender or comorbidities. Finally,  
263 fold change importance analysis performed on NP versus P patients highlighted IL-17A, MIP1 $\alpha$ ,  
264 IL-15, IL-8 and IFN $\gamma$  as the top five cytokines defining SARS-CoV-2 persistency (Fig. 4C).  
265 Altogether, bioinformatic analysis strongly suggests that a combination of early blood markers  
266 could predict prolonged SARS-CoV-2 infection.

267



268 **Fig. 4**



271 **Figure 4. Early immune signature of persistent patients.** (A) Heat map of cytokine  
272 concentration in serum from NI, NP and P at <10 DSSO measured by multiplex assay. K-means  
273 clustering was used to determine cytokine clusters 1-6 (cluster 1, n = 6; cluster 2, n = 6; cluster 3,  
274 n = 4; cluster 4, n = 7; cluster 5, n = 9; cluster 6, n = 4). (B) Correlation matrix across PBMC  
275 immunophenotyping and cytokines concentrations from NI, NP and P at <10 DSSO. Only  
276 significant correlations ( $p < 0.05$ ) are represented as dots. Pearson's correlation coefficients from  
277 comparisons of cytokine measurements within the same patients are visualized by color intensity.  
278 (C) Fold Change importance analysis between NP and P, calculated using the gtools package in  
279 R. IL-17A and MIP-1 $\alpha$  have median equals zero in NP, resulting in an infinite fold change, which  
280 is represented by the arrow.

281

282

### 283 **Longitudinal immune profiling of patients with prolonged SARS-CoV-2 infection**

284 Next, we analyzed the cytokine dynamics over the course of infection in the patients of our  
285 cohort (Fig. 5A, Suppl. Fig. A). Both IFN $\alpha$  and its target chemokine IP-10 progressively decreased  
286 over time in long-term carriers. Suppression of IP-10 has been proposed to be a mechanism of  
287 pathogen evasion and persistence in different infection models <sup>36</sup>. This trend could also be  
288 observed for IFN $\gamma$ , thus ruling out the possibility of a boost of systemic IFN responses leading to  
289 final viral clearance from the URT. Other cytokines went through a transient increase during the  
290 second week after symptom onset and finally dropped by the end of infection. This effect was  
291 particularly pronounced for TNF $\alpha$ , IL-12, IL-17A and IL-8, suggesting that these cytokines might  
292 contribute to SARS-CoV-2 clearance in the absence of efficient type I IFN responses.

293 To visualize the interplay between these cytokines and viral loads, we depicted cytokine  
294 concentrations along with Ct values (represented as Ct<sup>-1</sup>) for the eight individual patients with  
295 more than three longitudinal samples (Suppl. Fig. 6A). Instead of a unique immune profile, we  
296 found distinct cytokine and Ct dynamics. For instance, patient P11 had almost absent type 1  
297 immune responses and elevated concentrations of inflammatory and type 3 cytokines at the  
298 beginning of infection, and only IL-1 RA increased at later time points. Alternatively, patient P8  
299 began with overall lower cytokine concentrations that progressively increased, peaking at the third  
300 week after disease onset and shortly before viral clearance. Another illustrative example was  
301 patient P24, who remained infected by SARS-CoV-2 for the longest period of time (134 DSSO)  
302 and displayed strong viral replication during the first two weeks of infection, without evident  
303 alterations in plasma cytokine dynamics. Later on, an increase in TNF $\alpha$ , IFN $\gamma$  and IL-8 was  
304 apparent, coinciding with the stabilization of viral titers and final viral clearance. These data  
305 suggest that each long-term infected individual copes with viral persistence in a different manner.


306 Furthermore, we studied the behavior of different immune populations longitudinally.  
307 Generally, the immunophenotypic changes found during the first 10 days of SARS-CoV-2  
308 infection were maintained until the virus was cleared from the nasopharynx (Fig. 5B, Suppl. Fig.  
309 7A). Frequencies of classical, intermediate and non-classical monocytes only returned to control  
310 levels at time points where the virus was no longer detectable in the URT, and a similar trend was  
311 found for dendritic cell activation, monitored by the surface expression of HLA-DR. Additionally,  
312 most long-term carriers displayed lower pDC and NK cell frequencies all along the infection  
313 period.

314 Finally, in order to determine whether prolonged infection leads to progressive tissue  
315 damage, we quantified plasma concentrations of growth factors associated with wound repair

316 mechanisms. While VEGF concentrations acutely dropped at the second week after symptom  
317 onset, some patients showed a transient increase in PDGF-BB and basic FGF around this time  
318 point and stabilized later on, following the same trend as most inflammatory mediators (Fig. 5C,  
319 Suppl. Fig. 5A). Altogether, these results suggest that prolonged SARS-CoV-2 infection with low  
320 viral loads does not lead to persistent inflammation or to systemic tissue damage.

321

322 **Fig. 5**  
323



324

325 **Figure 5. Longitudinal immune profiling of persistent patients.** (A) Weekly longitudinal  
326 quantification of plasma cytokines in non-persistent (NP, blue) and persistent (P, red) patients by  
327 multiplex immunoassay. (B) Longitudinal immunophenotyping of PBMCs from NP and P  
328 depicting frequencies of CD14<sup>+</sup>CD16<sup>-</sup> classical monocytes (cMono) and CD14<sup>-</sup>CD16<sup>+</sup> non-  
329 classical monocytes (ncMono), mean fluorescence intensity (MFI) of HLA-DR in CD14<sup>-</sup>CD16<sup>-</sup>  
330 CD11c<sup>+</sup>CD141<sup>+</sup> (cDC1) and CD14<sup>-</sup>CD16<sup>-</sup>CD11c<sup>+</sup>CD1c<sup>+</sup> (cDC2), and frequencies of CD14<sup>-</sup>CD16<sup>-</sup>  
331 CD304<sup>+</sup> plasmacytoid cells (pDC) and CD3<sup>-</sup>CD56<sup>+</sup> natural killer cells (NK). Filled dots represent  
332 individual samples longitudinally collected at different time points until resolution of infection  
333 from patients positive by qRT-PCR for SARS-CoV-2, while empty dots represent samples from  
334 convalescent patients coinciding with the first negative qRT-PCR for SARS-CoV-2. (C) Weekly  
335 longitudinal quantification of VEGF and PDGF-BB in NP and P patients by multiplex magnetics  
336 bead-based immunoassay. Statistical significance was calculated using Mann-Whitney test or  
337 Kruskal-Wallis analysis followed by Dunn post-test and indicated by \*p % 0.05; \*\*p % 0.01; and  
338 \*\*\*p % 0.001. DSSO, Days since symptom onset.

339

340

### 341 **SARS-CoV-2 persistency favors the generation of Spike-specific neutralizing antibodies**

342 Adequate innate immune activation is essential for the development of antigen-specific  
343 adaptive immunity. Therefore, we next evaluated whether the distinct early immune profile that  
344 we found in long-term carriers would have consequences for the development of immunological  
345 memory. First, we analyzed different memory T cell populations over time. Some patients with  
346 persistent infection displayed higher frequencies of effector memory (EM) and terminally  
347 differentiated (EMRA) CD4<sup>+</sup> T cells over the course of infection (Fig. 6A, Suppl. Fig. 7A). We

348 also observed sustained elevated frequencies of circulating central memory (CM) and EM CD8<sup>+</sup>  
349 T cells until virus remission in this group of patients. Furthermore, in order to see whether long-  
350 term carriers were able to develop SARS-CoV-2-specific effector T cells, we isolated PBMCs at  
351 the convalescent phase and re-stimulated them *in vitro* with a pool of peptides spanning the Spike  
352 protein of the alpha variant of SARS-CoV-2. The results show no significant differences in actively  
353 proliferating T cells (Ki67<sup>+</sup>) between control COVID-19 patients and long-term carriers. Cytokine  
354 release by CD4<sup>+</sup> and CD8<sup>+</sup> T cells was comparable as well, except from IL-10 production by CD4<sup>+</sup>  
355 CD25<sup>+</sup> T cells, which was once again lower in the persistent group (Fig. 6B, C). These results  
356 indicate that persistent infection does not interfere with the development of antigen-specific T cell-  
357 mediated immune memory, and suggest that protective cellular mechanisms against re-infection  
358 are not impaired in long-term carriers.


359 Next, we aimed to study the development of antigen-specific humoral responses. We  
360 started analyzing follicular helper T cells (T<sub>FH</sub>), as they contribute to humoral immunity by  
361 delivering the necessary signals to B cells to enter germinal center and go through class-switch  
362 and affinity maturation. Although we did not find changes in the frequencies of circulating CD4<sup>+</sup>  
363 T<sub>FH</sub> cells (Fig. 6D), polyclonal stimulation of PBMCs collected at ≤ 14 DSSO revealed that this T  
364 cell population produced higher amounts of IL-21 in long-term carriers, being this cytokine  
365 essential for B cell help (Fig. 6E). Furthermore, we compared the composition of the B cell  
366 compartment and the development of humoral responses in patients with normal or delayed  
367 resolution of infection. We did not observe significantly different frequencies of circulating  
368 mature, class-switched B cells, although the proportion of circulating plasmablasts/plasma cells  
369 dropped in long-term carriers after 14 DSSO (Fig. 6F, Suppl. Fig. 6A). Serological analysis did  
370 not identify significant alterations in the production of nucleocapsid (N) protein-specific IgG

371 (Suppl. Fig. 8A) or spike protein-specific IgM, IgG and IgA antibodies over time (Fig. 6G, Suppl.  
372 Fig. 8A). However, plasma of long-term carriers displayed higher titers of circulating neutralizing  
373 antibodies against all analyzed SARS-CoV-2 variants three weeks after symptoms onset, and at  
374 least until the patients reached the convalescent phase (Fig. 6H, Suppl. Fig. 8B). These data suggest  
375 that development of systemic N protein- of spike protein-specific humoral responses do not seem  
376 to be sufficient for viral clearance during primary SARS-CoV-2 infection, although it may confer  
377 better protection against re-infection in long-term carriers.

378



379 **Fig. 6**



380

381 **Figure 6. Profiling of cellular and serological adaptive response of persistent patients. (A)**  
382 Longitudinal immunophenotyping of PBMC from NP and P depicting  $CD4^+CD27^-CD45RA^-$   
383  $CCR7^+$  type 2 effector memory T cells (EM2),  $CD4^+CD27^-CD45RA^+CCR7^-$  terminally  
384 differentiated effector memory T cells (EMRA),  $CD8^+CD27^+CD45RA^-CCR7^+$  central memory T  
385 cells (CM), and  $CD8^+CD27^-CD45RA^-CCR7^-$  type 1 effector memory T cells (EM1). Filled dots  
386 represent individual samples longitudinally collected until resolution of infection from NP and P  
387 patients positive by qRT-PCR for SARS-CoV-2. Empty dots represent samples from convalescent  
388 patients coinciding with the first negative qRT-PCR for SARS-CoV-2. (B, C)  
389 Immunophenotyping of SARS-CoV-2 reactive CD4 and CD8 T cells after *in vitro* stimulation of  
390 PBMC from NP ( $n=11$ ) and P ( $n=9$ ) after viral clearance with peptides spanning the Spike protein  
391 of the alpha variant of SARS-CoV-2. Percentage of (B)  $CD4^+$  and  $CD8^+$  cells expressing Ki67,  
392 (C)  $CD4^+$  cells expressing  $TNF\alpha$ ,  $CD8^+$  cells expressing  $IFN\gamma$  and Granzyme B (Grz B), and  
393  $CD4^+CD25^+$  cells expressing IL-10. (D) Longitudinal immunophenotyping of PBMC from NP and  
394 P depicting  $CD3^+CD4^+CXCR5^+$  and  $CD3^+CD8^+CXCR5^+$  follicular T (TFH) cells. (E) Percentage  
395 of  $CD4^+CXCR5^+$  T cells expressing IL-21 after polyclonal *in vitro* stimulation of PBMC from NP  
396 ( $n=11$ ) and P ( $n=24$ ) at <14 DSSO with anti CD3/CD28 beads. (F) Longitudinal  
397 immunophenotyping of PBMC from NP ( $n=7$ ) and P ( $n=10$ ) depicting  $CD27^+CD38^-$  switched  
398 immunoglobulin (swIg) memory B cells (MBC) and plasmablast/plasma cells (PB/PC). (G)  
399 Longitudinal assessment of Spike-specific IgG and IgA antibodies in plasma from P and NP by  
400 ELISA assay. (H) Titers of neutralizing antibodies against Alpha S1, Beta S1, Gamma RBD, and  
401 Kappa RBD variants of SARS-CoV-2 in plasma from NP and P around 21 DSSO and P by the  
402 time of viral clearance by multiplex neutralization assay. Statistical significance was calculated

403 using Mann-Whitney test or Kruskal-Wallis analysis followed by Dunn post-test and indicated by  
404 \*p % 0.05; \*\*p % 0.01; and \*\*\*p % 0.001. DSSO, Days since symptom onset.

405

## 406 **DISCUSSION**

407 Our cohort comprises a group of oligosymptomatic patients with persistent infection who,  
408 by definition, have low resistance and high disease tolerance. Here we show that low resistance in  
409 these patients is likely due to impaired innate antiviral immunity, as no major defects in adaptive  
410 immunity were found. Furthermore, we observed divergent cytokine profiles systemically and in  
411 the nasopharyngeal mucosa, in line with other studies recently published<sup>37</sup>. Major differences in  
412 cytokines, chemokines and growth factors were found in the plasma of patients with prolonged  
413 course of infection early after disease onset. However, although relevant mucosal cytokines, such  
414 as IL-17A and IL-10, were not altered in the nasopharynx, we cannot exclude the contribution of  
415 cytokines with only transient induction or other mucosal mediators not studied here.

416

417 Systemically, long-term carriers displayed decreased frequencies of circulating classical  
418 monocytes and pDCs shortly after symptom onset, being the latter essential for the control of viral  
419 replication through the rapid release of IFN-I<sup>31,32,38</sup>. Early IFN-I triggers different mechanisms  
420 targeting virally infected cells, namely the expression of antiviral proteins, the activation of NK  
421 cells and the initiation of Th1 responses. Each one of these elements was underrepresented in those  
422 COVID-19 patients who later on presented persistent infection. Thus, our data suggest that early  
423 systemic immunological patterns may indicate future persistency of SARS-CoV-2 infection in  
424 immunocompetent patients.

425

426           Moreover, long-term carriers displayed an immunological shift characterized by a low  
427 systemic Th1/2 signature, increasing in turn IL-17A, IL-8 and other neutrophil-recruiting  
428 chemokines. In line with our data, mouse models of chronic infection by TMEV also link Th17  
429 cells to viral persistence<sup>39</sup>. Impaired IFN-I responses and an enhanced type 3 signature are traits  
430 that had been previously associated with severe COVID-19<sup>9-11</sup>. Conversely, inflammatory and  
431 Th1/2 responses are elevated in patients with severe symptoms but low in oligosymptomatic long-  
432 term carriers, which suggests their involvement in the pathogenesis of COVID-19<sup>7-9,13</sup>. Further  
433 studies to better characterize the correlation of these immunological patterns with infectious  
434 disease outcome are warranted.

435

436           The engagement of disease tolerance mechanisms, like enhanced tissue repair, metabolic  
437 adaptations or immune regulation, may also lead to distinct disease trajectories<sup>40,41</sup>. Our data could  
438 not identify enhanced systemic tissue repair or regulatory responses during the course of prolonged  
439 SARS-CoV-2 infection. The immunoregulatory cytokine IL-10, which is commonly linked to  
440 immunological tolerance, but also a well-accepted disease marker in COVID-19<sup>42,43</sup>, was  
441 particularly low in long-term carriers. In order to understand the physiological meaning of this  
442 effect and the involvement of additional disease tolerance mechanisms, further analysis should be  
443 conducted.

444

445           In our study, long-term SARS-CoV-2 carriers had higher titers of neutralizing Spike-  
446 specific antibodies already three weeks after symptom onset. First, this indicates that systemic  
447 neutralizing antibodies are not sufficient for viral clearance from the URT during primary  
448 infection. Type I IFNs may contribute to this effect, since they have been associated with

449 modulation of B cell responses and antibody production in the context of viral infection <sup>44,45</sup>.  
450 Furthermore, patients with severe COVID-19, who may remain infected for extended time periods  
451 and present dysregulated IFN-I and type 3 responses, have also been shown to produce higher  
452 titers of neutralizing antibodies <sup>46</sup>. Together with our data, this suggests that dampened IFN-I  
453 responses and/or strong type 3 immunity in persistent SARS-CoV-2 infection might confer  
454 advantages against re-infection. On the other hand, these antibodies might also contribute to viral  
455 persistence via antibody-dependent enhancement or modulate COVID-19 immunopathology via  
456 Fc-receptors. Hence, analysis of the functionality of the antibodies elicited during long-term  
457 infection, and longer follow-up of the adaptive cellular and humoral immunity in these patients  
458 could be valuable for COVID-19 treatment and vaccine design and development.

459

460         Given the out-care characteristic of our cohort and the techniques available, our  
461 investigation of viral RNA was restricted to nasopharyngeal samples. Assessment of viral titers in  
462 various tissues would allow for a better understanding of whether long-term carriers display  
463 systemic low resistance, or if this phenomenon is restricted to the mucosal site. Although we did  
464 not find increased damage and tissue repair markers in the blood or in the nasal mucosa, we cannot  
465 exclude that other SARS-CoV-2 target tissues, such as the lungs or the gut, have altered disease  
466 tolerance or support viral replication. To study disease tolerance and viral presence in such  
467 locations, animal models for SARS-CoV-2 would be helpful. Furthermore, our samples are limited  
468 and were collected in a specific timing and geographical context of the pandemic. Nonetheless, to  
469 our knowledge, the present study constitutes the characterization of immune parameters in the  
470 larger number of immunocompetent oligosymptomatic patients with persistent infection of SARS-

471 CoV-2 so far. Still, sample size is critical when studying such a heterogeneous disease as COVID-  
472 19, and, therefore, validation of our data in larger, independent cohorts would be informative.

473

474 Collectively, our study provides a thorough analysis of the immune dynamics during viral  
475 persistency in COVID-19 patients. Over the past two years, important progress has been made in  
476 controlling the pandemic, but the vaccines available, though successful in limiting disease, are not  
477 sterilizing and do not completely prevent transmission of new SARS-CoV-2 variants <sup>47</sup>. In  
478 COVID-19 as well as in other viral infections, oligosymptomatic and asymptomatic carriers  
479 represent the main vector of viral transmission. Therefore, long-term immunocompetent infected  
480 individuals are potential long-term spreaders and may, additionally, facilitate intra-host evolution  
481 of SARS-CoV-2 and other viruses <sup>17,22,23</sup>. This reinforces the need for a better understanding of  
482 the immune mechanisms of viral control in these patients. All in all, our study identifies a set of  
483 early plasma markers associated with prolonged infection and reveals alternative immunological  
484 strategies to deal with viral infection without major tissue damage.

485

486

487 **Acknowledgments:** This work was partially supported by ANRS | Maladies infectieuses  
488 émergentes/INSERM grant (MUCOVID-007) (to DK and MTB); by CAPES, Edital de Seleção  
489 Emergencial II CAPES grant 88887.507381/2020-00 (to MTB); by Fundação de Amparo à  
490 Pesquisa do Estado do Rio de Janeiro (FAPERJ), grant E-26/201.128/2022 (272688) and E-  
491 26/211.564/2019 (252360) (to MTB), E-26/010.002434/2019 and E-26/210.178/2020 (to AT), E-  
492 26/203.002/208 (to A.M.V.); by Conselho Nacional de Desenvolvimento Científico e Tecnológico  
493 (CNPq) grant 312477/2021-0 (to MTB) and grants 439649/2018-8 and 316796/2021-2 (to  
494 A.M.V.); Instituto Serrapilheira (to AT).

495 EM-C; VCB; GSL; VAO were supported by fellowships from CAPES (88887.507381/2020-00).

496 CM; CC; LC were supported by fellowships from FAPERJ  
497 DASR was supported by a fellowship from CNPq (DTI-A; 401209/2020-2).  
498 ICL was supported by a fellowship from CNPq  
499 JCRF and LZR were supported by fellowships from ANRS/INSERM (MUCOVID-007)  
500 HDRF; CSC; VMV; AMS were supported by fellowships from CAPES

501

502 **Author contributions:**

503 Conceptualization: EM-C; VCB; CM; AT; DK; AMV; TMC; JE-L; MTB  
504 Methodology: EM-C; VCB; CM; JE-L; MTB  
505 Investigation: EM-C; VCB; CM; JCRF; HDRF; CSC; DASR; AMS; VMV; LSA; LZR; GSL;  
506 VAO; CC; LC; ICL; JE-L  
507 Formal analysis: EM-C; VCB; CM; JCRF; CC; DASR; RMP; AMV; JE-L; MTB  
508 Visualization: EM-C; VCB; JE-L; MTB  
509 Funding acquisition: AT; DK; AMV; TMC; MTB  
510 Project administration: EM-C; AT; AMV; TMC; JE-L; MTB  
511 Supervision: EM-C; AT, OCF; AMV; TMC; JE-L; MTB  
512 Writing – original draft: EM-C; VCB; CM; DK; JE-L; MTB  
513 Writing – review & editing: EM-C; VCB; CM; AT; OCF; RMP; DK; AMV; TMC; JE-L;  
514 MTB

515

516 **Competing interests:** Authors declare that they have no competing interests

517

518

519

520

521 **STAR Methods**

## 522 Cohort and Study Design

523 All patients included in the present study sought testing at the Diagnostic Screening Center  
524 for COVID-19 at the Federal University of Rio de Janeiro (CTD-UFRJ) and declared written  
525 informed consent. From April to December 2020, we enrolled two thousand seven hundred and  
526 fifty-nine patients who were tested for SARS-CoV-2 infection at the Diagnostic Screening Center  
527 for COVID-19 of the Federal University of Rio de Janeiro (CTD-UFRJ). Among them, 1,133  
528 individuals (41.07%) tested positive for the presence of SARS-CoV-2 RNA by quantitative PCR  
529 with reverse transcription (RT-qPCR) on nasopharyngeal swab samples. Those individuals were  
530 offered weekly follow-up testing until SARS-CoV-2 RNA was no longer detected. Blood from  
531 those patients was collected in heparinized tubes for plasma and PBMC storage and further  
532 analysis. Symptoms, use of medication, comorbidities and demographic information were assessed  
533 by oral questionnaire performed by trained personnel. Based on blood sample availability, 33  
534 patients were selected from those with persistent SARS-CoV-2 infection, defined as positive  
535 SARS-CoV-2 RT-qPCR in upper respiratory tract (URT) samples after 21 days after symptom  
536 onset. As such, 32 patients were selected from those who did not display persistent viral RNA,  
537 defined as a negative SARS-CoV-2 RT-qPCR in URT samples up to 21 days after symptom onset.  
538 The criterion was guided by the median of positivity duration in the overall cohort, which was  
539 around three weeks (Voloch et al, 2021). Twenty-five non-infected volunteers were included as  
540 controls, defined as a negative SARS-CoV-2 qRT-PCR, no history of a positive SARS-CoV-2  
541 qRT-PCR and no seroconversion for SARS-CoV-2 epitopes. All procedures and experiments were  
542 approved by the correspondent Ethic Committee Board (CAAE: 30161620.0.1001.5257;  
543 4.245.490).

544



## 545 **PBMC and plasma isolation**

546 PBMCs were isolated from blood collected in lithium heparin tubes by Ficoll–Hypaque  
547 density gradient centrifugation. Briefly, blood was layered on a density gradient (Hystopaque®  
548 1077, Sigma-Aldrich), and PBMCs were separated by centrifuging at 400 rcf for 30 min. PBMCs  
549 were washed four times in phosphate-buffered saline (PBS), submitted to ACK for 5 min to lyse  
550 red blood cells, and frozen in liquid nitrogen in 90% fetal bovine serum (FBS) with 10% DMSO  
551 (Sigma-Aldrich) until used for flow cytometry and stimulation assays. Plasma samples were  
552 collected in 10-ml tubes in lithium heparin tubes, centrifuged at 400 rcf for 10 min, aliquoted, and  
553 stored at  $-20^{\circ}\text{C}$  for further experiments.

554

## 555 **Cell culture**

556 PBMCs were thawed in RPMI 1640 medium (Lonza) supplemented with 10% FBS  
557 (Gibco™) and penicillin (100 IU/ml; Gibco™)/streptomycin (100  $\mu\text{g}/\text{ml}$ ; Gibco™). For T cell  
558 stimulation,  $0.5 \times 10^6$  PBMCs were cultured in 500  $\mu\text{l}$  of medium in a 24-well flat-bottomed  
559 microplate and stimulated for 4 days with anti-CD3/anti-CD28 Dynabeads™ Human T-activator  
560 (10  $\mu\text{L}/\text{mL}$ , Gibco™). For detection of SARS-CoV-2–specific  $\text{CD4}^+$  and  $\text{CD8}^+$  T cells,  $0.5 \times 10^6$   
561 PBMC cells were stimulated in a 96-well U-bottom plate for 7 days in 200  $\mu\text{l}$  of medium containing  
562 1  $\mu\text{g}/\text{ml}$  of SARS-CoV-2 variant Spike peptide pools (JPT Peptide Technologies) in the presence  
563 of IL-2r (20UI, PrepoTech Inc.). As a control, some cells were maintained with IL-2r alone. After  
564 6 days, the cells were re-stimulated with 10  $\mu\text{g}/\text{ml}$  of the aforementioned peptide pools overnight.  
565 In order to optimize the detection of intracellular cytokines, Brefeldin A (10  $\mu\text{g}/\text{mL}$ ; BD  
566 Biosciences, San Diego, CA, USA) was added in the last 4 h (for Dynabeads™) or 12h (for SARS-  
567 CoV-2 peptide pools) of the cell cultures. Cultures were maintained in a humidified incubator with

568 5% CO<sub>2</sub> at 37°C. After stimulation, cells were stained for proliferation and/or phenotypic  
569 lymphocyte markers by Flow Cytometry.

570

## 571 **Flow Cytometry**

572 Staining for flow cytometry analysis was performed using fluorescently-labeled specific  
573 anti-human antibodies. Unless otherwise stated, antibodies were purchased from Biolegend: IgD-  
574 PE-Cy7, CD15-BV421, CD56-PE-CF594, CD14-PECy5, CD16-BV786, HLA-DR-  
575 BB515/PECy5 (BD Bioscience), CD11b-APC-Cy7, CD304-PE, CD11c-BV711, CD1c-APC,  
576 CD141-BV650, CD3-BV510/BV605, CD4-BV785, CD19-BV421/BV510, CD8-BV711/APC-  
577 Fire750, CD27-FITC/PE, CCR7-BV421, CD45RA-PE-Cy7/PE-Cy5, CD25-AF700, PD-1-PE,  
578 CD38-BV711/PE-Cy5, CXCR5-PE-CF594, Ki67-APC, IL-10-BV421, Granzyme B-FITC (BD  
579 Bioscience), IFN $\gamma$ -APC-Fire750, TNF $\alpha$ -BV650, IL-9-PE, IL-6-PE/PE-Cy7, and IL-21-PerCP-  
580 Cy5.5.

581 Briefly,  $5 \times 10^5$  cells were incubated with LIVE/DEAD Fixable Aqua Dead Cell staining  
582 (1:1000, BV510; Invitrogen) in PBS for 30 min, and washed with PBS containing 3% FBS and  
583 0.01% sodium azide. Next, cells were incubated with the fluorescently-labelled antibodies for 30  
584 min at room temperature in the dark. When intracellular staining was required, cells were  
585 permeabilized with the Cytofix/Cytoperm solution (BD Pharmigen) at 4°C for 20 min and  
586 subsequently incubated for 30 min at 4°C with the appropriate antibodies. Events were acquired  
587 on LSR FORTESSA X-20 (BD Biosciences). Target cells were gated based on forward and side  
588 scatter properties, singlets and living cells were analyzed by using FlowJo<sup>®</sup> Software. FMO  
589 controls and single-stained samples were used to periodically check the settings and gates on the  
590 flow cytometer.

591

## 592 **Quantification of inflammatory, anti-inflammatory, and antiviral mediators**

593 Cytokines and immune mediators were quantified with a multiplex magnetic bead-based  
594 immunoassay according to the manufacturer's instructions, using the Bio-Plex Pro™ Human  
595 Cytokines 27-Plex Assay (BIO-RAD) and the Human ProcartaPlex™ kit (Invitrogen™,  
596 ThermoFisher Scientific), including the following analytes: basic FGF, Eotaxin, G-CSF, GM-CSF,  
597 IFN- $\gamma$ , IL-1 $\beta$ , IL-1RA, IL-2, IL-4, IL-5, IL-7, IL-8, IL-9, IL-10, IL-12 (p70), IL-13, IL-15, IL-  
598 17A, IP-10/CXCL10, MCP-1/CCL2, MIP-1 $\alpha$ /CCL3, MIP-1 $\beta$ /CCL4, PDGF-BB, TNF- $\alpha$ , and  
599 VEGF, IFN $\alpha$ , IFN $\beta$ , IFN $\Omega$ , IL-29, IL-18, IL-21, syndecan, ferritin. Data were acquired in a  
600 Luminex MAGIPIX® System (serial number MAGPX11266003) using the XPONENT software.  
601 Additionally, IL-6, and RANTES/CCL5 concentrations were determined in plasma samples by  
602 enzyme-linked immunosorbent assay (Human IL-6 and RANTES/CCL5 TMB ELISA,  
603 Peprotech), according to the manufacturer's instructions. Absorbance was measured in a  
604 SpectraMax® microplate reader (Molecular Device).

605

## 606 **Quantitative PCR**

607 RNA from PBMCs was extracted using Fastzol (QuatroG, Brazil), according to the  
608 manufacturer's instructions. 1  $\mu$ g of RNA was reverse transcribed to complementary DNA (cDNA)  
609 with the High-Capacity RNA-to-cDNA™ Kit (Applied Biosystems™) and random primers.  
610 Quantitative RT-PCR was performed with the Power SYBR® Green PCR Master Mix (Applied  
611 Biosystems™) in an ABI 7500 instrument (Applied Biosystems™). Ct values were normalized to

612 the mRNA expression of GAPDH and relative expression was calculated with the  $\Delta\Delta C_t$  method.  
613 Primer sequences are available upon request.

614

### 615 **Determination of SARS-CoV-2 specific immunoglobulins and neutralizing antibodies**

616 Anti-SARS-CoV-2 spike protein IgM, IgA, and IgG antibodies were quantified by enzyme-  
617 linked immunosorbent assay, following the *S-UFRJ test* protocol, as previously described <sup>48</sup>.  
618 Briefly, serial dilutions of plasma samples (starting 1:40, in PBS 1% BSA) were incubated in high-  
619 binding ELISA plates previously coated with 50  $\mu$ L of SARS-CoV-2 spike protein (4  $\mu$ g/mL)  
620 overnight. Antibodies were detected with goat anti-human IgG, IgA, and IgM (Fc)-horseradish  
621 peroxidase antibodies (Southern Biotech) and developed with TMB (Scienco). Optical density  
622 (OD) was measured in a SpectraMax<sup>®</sup> microplate reader (Molecular Device, USA). Plasma titers  
623 of neutralizing antibodies were quantified with a multiplex magnetic bead-based immunoassay,  
624 using the Bio-Plex Pro Human SARS-CoV-2 Neutralization Antibody Assay (BIO-RAD)  
625 according to the manufacturer's instructions.

626

### 627 **Statistical analysis**


628 One-dimensional probability distributions of samples were analyzed by Kolmogorov–  
629 Smirnov test. Statistical analysis was performed by one-way variance analysis followed by  
630 Bonferroni post-test for samples with normal distribution; or Kruskal-Wallis analysis followed by  
631 Dunn post-test. Correlations were analyzed by Spearman's rank correlation coefficient. The  
632 statistical analysis was performed using Prism 8.0 software (GraphPad Software, San Diego, CA).

It is made available under a [CC-BY 4.0 International license](#) .

634 **Supplementary Material**

635 **Suppl. Fig. 1.**


A



636

637 **Suppl. Fig. 1. Cytokine analysis in swab samples at disease onset.** Cytokine quantification in  
638 swabs samples from upper respiratory tract of NP (n=9) and P (n=13) at <10 DSSO by multiplex  
639 magnetics bead-based immunoassay. Each dot represents a subject. Filled dots represent a positive  
640 qRT-PCR of nasopharyngeal samples for SARS-CoV-2. Statistical significance was calculated  
641 using Mann-Whitney test.  
642

643 **Suppl. Fig. 2.**






645 **Suppl. Fig. 2. Flow cytometry gating strategies.** Gating strategies on PBMCs for  
646 immunophenotyping of (A) innate immune cells, among them NK cells, monocytes and dendritic  
647 cells, (B) T lymphocytes and (C) B lymphocytes.

648

649 **Suppl. Fig. 3.**



650

651



652 **Suppl. Fig. 3. Immunophenotyping and plasma cytokine analysis at disease onset.**

653 Immunophenotyping of major innate immune cell populations in PBMC (A) LIVE/DEAD<sup>-</sup>CD3<sup>-</sup>  
654 CD19<sup>-</sup>CD56<sup>-</sup> (lin<sup>-</sup>) CD14<sup>-</sup>CD16<sup>-</sup>CD11c<sup>+</sup>CD141<sup>+</sup> type 1 dendritic cells (cDC1), LIVE/DEAD<sup>-</sup>lin<sup>-</sup>  
655 CD14<sup>-</sup>CD16<sup>-</sup>CD11c<sup>+</sup>CD1c<sup>+</sup> type 2 dendritic cells (cDC2) and LIVE/DEAD<sup>-</sup>lin<sup>-</sup>HLA<sup>-</sup>DR<sup>-</sup>CD14<sup>+</sup>  
656 myeloid-derived suppressor cells (MoMDSCs). (B) MFI of HLA-DR in cMono, iMono, ncMono,  
657 cDC1 and cDC2 cell populations. (C) Quantification of plasma cytokines in non-infected  
658 individuals (NI), non-persistent patients (NP) and persistent patients (P) at <10 DSSO by multiplex  
659 magnetics bead-based immunoassay. Each dot represents a different subject. Statistical  
660 significance was calculated using Mann-Whitney test or Kruskal-Wallis analysis followed by  
661 Dunn post-test and indicated by \*p % 0.05; \*\*p % 0.01; and \*\*\*p % 0.001. DSSO, Days since  
662 symptom onset.

663


It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

664 **Suppl. Fig. 4**



666 **Suppl. Fig. 4. Cluster analysis of immunophenotyping and plasma cytokine data at disease**  
667 **onset.** (A) Heat map of blood cell populations and cytokine concentration in serum from P, NP  
668 and NI at <10 DSSO measured by flow cytometry and Luminex assay. K-means clustering was  
669 used to determine cytokine clusters 1-7). Measurements were normalized across all patients by Z-  
670 score. (B) t-Distributed Stochastic Neighbor Embedding (t-SNE) probabilistic dimensionality  
671 reduction technique applied in PBMC immunophenotyping and cytokines concentration at <10  
672 DSSO from 51 patients (P, Blue,  $n=27$ ; NP, Orange,  $n=19$ ; NI, Green,  $n=5$ ). Measurements were  
673 normalized across all patients by Z-score.  
674

675 **Suppl. Fig. 5.**




676

677 **Suppl. Fig. 5. Longitudinal cytokine analysis.** (A) Weekly longitudinal quantification of plasma  
678 cytokines in non-persistent (NP, blue) and persistent (P, red) patients by multiplex magnetic bead-  
679 based immunoassay.

680


681 **Suppl. Fig. 6**



It is made available under a [CC-BY 4.0 International license](#) .




690 **Suppl. Fig. 7**




692 **Suppl. Fig. 7. Longitudinal analysis of immune cell populations.** Longitudinal  
693 immunophenotyping in PBMC of NP and P patients. Filled dots represent individual samples  
694 longitudinally collected at different time points until resolution of infection from patients positive  
695 by qRT-PCR for SARS-CoV-2, while empty dots represent samples from convalescent patients  
696 coinciding with the first negative qRT-PCR for SARS-CoV-2. Statistical significance was  
697 calculated using Mann-Whitney test or Kruskal-Wallis analysis followed by Dunn post-test and  
698 indicated by \*p % 0.05; \*\*p % 0.01; and \*\*\*p % 0.001.  
699

700 **Suppl. Fig. 8**

**A**



**B**



701

702

703 **Suppl. Fig. 8. Longitudinal analysis of SARS-CoV-2-specific immunoglobulins and**

704 **neutralizing antibodies.** Longitudinal assessment of anti-N IgG and anti-S IgM antibodies in

705 plasma from P and NP by ELISA assay. (H) Titers of neutralizing antibodies against S1, D614G

706 S1, RBD, Epsilon RBD, K417N RBD, E484K RBD, and N501Y RBD variants of SARS-CoV-2

707 in plasma from NP and P around 21 DSSO and P by the time of viral clearance by competitive

708 Luminex multiplex neutralization assay. Statistical significance was calculated using Mann-

709 Whitney test or Kruskal-Wallis analysis followed by Dunn post-test and indicated by \*p % 0.05;

710 \*\*p % 0.01; and \*\*\*p % 0.001. DSSO, Days since symptom onset.

711

712

## 713 References

- 714 1. Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et  
715 al. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan,  
716 China. *Lancet Lond. Engl.* *395*, 497–506. [10.1016/S0140-6736\(20\)30183-5](https://doi.org/10.1016/S0140-6736(20)30183-5).
- 717 2. Liu, L., Lei, X., Xiao, X., Yang, J., Li, J., Ji, M., Du, W., Tan, H., Zhu, J., Li, B., et al.  
718 (2020). Epidemiological and Clinical Characteristics of Patients With Coronavirus Disease-  
719 2019 in Shiyuan City, China. *Front. Cell. Infect. Microbiol.* *10*.
- 720 3. Nogrady, B. (2020). What the data say about asymptomatic COVID infections. *Nature* *587*,  
721 534–535. [10.1038/d41586-020-03141-3](https://doi.org/10.1038/d41586-020-03141-3).
- 722 4. He, X., Lau, E.H.Y., Wu, P., Deng, X., Wang, J., Hao, X., Lau, Y.C., Wong, J.Y., Guan, Y.,  
723 Tan, X., et al. (2020). Temporal dynamics in viral shedding and transmissibility of COVID-  
724 19. *Nat. Med.* *26*, 672–675. [10.1038/s41591-020-0869-5](https://doi.org/10.1038/s41591-020-0869-5).
- 725 5. Verity, R., Okell, L.C., Dorigatti, I., Winskill, P., Whittaker, C., Imai, N., Cuomo-  
726 Dannenburg, G., Thompson, H., Walker, P.G.T., Fu, H., et al. (2020). Estimates of the  
727 severity of coronavirus disease 2019: a model-based analysis. *Lancet Infect. Dis.* *20*, 669–  
728 677. [10.1016/S1473-3099\(20\)30243-7](https://doi.org/10.1016/S1473-3099(20)30243-7).
- 729 6. Williamson, E.J., Walker, A.J., Bhaskaran, K., Bacon, S., Bates, C., Morton, C.E., Curtis,  
730 H.J., Mehrkar, A., Evans, D., Inglesby, P., et al. (2020). Factors associated with COVID-19-  
731 related death using OpenSAFELY. *Nature* *584*, 430–436. [10.1038/s41586-020-2521-4](https://doi.org/10.1038/s41586-020-2521-4).
- 732 7. Giamarellos-Bourboulis, E.J., Netea, M.G., Rovina, N., Akinosoglou, K., Antoniadou, A.,  
733 Antonakos, N., Damoraki, G., Gkavogianni, T., Adami, M.-E., Katsaounou, P., et al. (2020).  
734 Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure.  
735 *Cell Host Microbe* *27*, 992-1000.e3. [10.1016/j.chom.2020.04.009](https://doi.org/10.1016/j.chom.2020.04.009).
- 736 8. Mathew, D., Giles, J.R., Baxter, A.E., Oldridge, D.A., Greenplate, A.R., Wu, J.E., Alanio,  
737 C., Kuri-Cervantes, L., Pampena, M.B., D’Andrea, K., et al. (2020). Deep immune profiling  
738 of COVID-19 patients reveals distinct immunotypes with therapeutic implications. *Science*.  
739 [10.1126/science.abc8511](https://doi.org/10.1126/science.abc8511).
- 740 9. Lucas, C., Wong, P., Klein, J., Castro, T.B.R., Silva, J., Sundaram, M., Ellingson, M.K.,  
741 Mao, T., Oh, J.E., Israelow, B., et al. (2020). Longitudinal analyses reveal immunological  
742 misfiring in severe COVID-19. *Nature* *584*, 463–469. [10.1038/s41586-020-2588-y](https://doi.org/10.1038/s41586-020-2588-y).
- 743 10. Bastard, P., Rosen, L.B., Zhang, Q., Michailidis, E., Hoffmann, H.-H., Zhang, Y., Dorgham,  
744 K., Philippot, Q., Rosain, J., Béziat, V., et al. (2020). Autoantibodies against type I IFNs in  
745 patients with life-threatening COVID-19. *Science* *370*, eabd4585. [10.1126/science.abd4585](https://doi.org/10.1126/science.abd4585).
- 746 11. Lopez, J., Mommert, M., Mouton, W., Pizzorno, A., Brengel-Pesce, K., Mezidi, M., Villard,  
747 M., Lina, B., Richard, J.-C., Fassier, J.-B., et al. (2021). Early nasal type I IFN immunity  
748 against SARS-CoV-2 is compromised in patients with autoantibodies against type I

- 749 IFNsImpact of nasal IFN-I autoantibodies in COVID-19. *J. Exp. Med.* 218, e20211211.  
750 10.1084/jem.20211211.
- 751 12. Zhang, Q., Bastard, P., Liu, Z., Le Pen, J., Moncada-Velez, M., Chen, J., Ogishi, M., Sabli,  
752 I.K.D., Hodeib, S., Korol, C., et al. (2020). Inborn errors of type I IFN immunity in patients  
753 with life-threatening COVID-19. *Science* 370, eabd4570. 10.1126/science.abd4570.
- 754 13. Bergamaschi, L., Mescia, F., Turner, L., Hanson, A.L., Kotagiri, P., Dunmore, B.J.,  
755 Ruffieux, H., Sa, A.D., Huhn, O., Morgan, M.D., et al. (2021). Longitudinal analysis reveals  
756 that delayed bystander CD8+ T cell activation and early immune pathology distinguish  
757 severe COVID-19 from mild disease. *Immunity* 54, 1257-1275.e8.  
758 10.1016/j.immuni.2021.05.010.
- 759 14. Bost, P., Giladi, A., Liu, Y., Bendjelal, Y., Xu, G., David, E., Blecher-Gonen, R., Cohen, M.,  
760 Medaglia, C., Li, H., et al. (2020). Host-viral infection maps reveal signatures of severe  
761 COVID-19 patients. *Cell*, S0092867420305687. 10.1016/j.cell.2020.05.006.
- 762 15. Schneider, D., and Ayres, J. (2008). Two ways to survive infection: what resistance and  
763 tolerance can teach us about treating infectious diseases. *Nat. Rev. Immunol.* 8.  
764 10.1038/nri2432.
- 765 16. Medzhitov, R., Schneider, D.S., and Soares, M.P. (2012). Disease Tolerance as a Defense  
766 Strategy. *Science* 335, 936–941. 10.1126/science.1214935.
- 767 17. Choi, B., Choudhary, M.C., Regan, J., Sparks, J.A., Padera, R.F., Qiu, X., Solomon, I.H.,  
768 Kuo, H.-H., Boucau, J., Bowman, K., et al. (2020). Persistence and Evolution of SARS-  
769 CoV-2 in an Immunocompromised Host. *N. Engl. J. Med.* 383, 2291–2293.  
770 10.1056/NEJMc2031364.
- 771 18. Avanzato, V.A., Matson, M.J., Seifert, S.N., Pryce, R., Williamson, B.N., Anzick, S.L.,  
772 Barbian, K., Judson, S.D., Fischer, E.R., Martens, C., et al. (2020). Case Study: Prolonged  
773 Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual  
774 with Cancer. *Cell* 183, 1901-1912.e9. 10.1016/j.cell.2020.10.049.
- 775 19. Tarhini, H., Recoing, A., Bridier-Nahmias, A., Rahi, M., Lambert, C., Martres, P., Lucet, J.-  
776 C., Rioux, C., Bouzid, D., Lebourgeois, S., et al. (2021). Long-Term Severe Acute  
777 Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infectiousness Among Three  
778 Immunocompromised Patients: From Prolonged Viral Shedding to SARS-CoV-2  
779 Superinfection. *J. Infect. Dis.* 223, 1522–1527. 10.1093/infdis/jiab075.
- 780 20. Truong, T.T., Ryutov, A., Pandey, U., Yee, R., Goldberg, L., Bhojwani, D., Aguayo-Hiraldo,  
781 P., Pinsky, B.A., Pekosz, A., Shen, L., et al. (2021). Increased viral variants in children and  
782 young adults with impaired humoral immunity and persistent SARS-CoV-2 infection: A  
783 consecutive case series. *eBioMedicine* 67. 10.1016/j.ebiom.2021.103355.
- 784 21. Ayres, J.S. (2020). Surviving COVID-19: A disease tolerance perspective. *Sci. Adv.* 6,  
785 eabc1518. 10.1126/sciadv.abc1518.

- 786 22. Voloch, C.M., F. R. da S., Almeida, L.G.P. de, Brustolini, O.J., Cardoso, C.C., Gerber, A.L.,  
787 Guimarães, A.P. de C., Leitão, I. de C., Mariani, D., Ota, V.A., et al. (2020). Intra-host  
788 evolution during SARS-CoV-2 persistent infection 10.1101/2020.11.13.20231217.
- 789 23. Leitão, I. de C., Calil, P.T., Galliez, R.M., Moreira, F.R.R., Mariani, D., Castiñeiras, A.C.P.,  
790 da Silva, G.P.D., Maia, R.A., Corrêa, I.A., Monteiro, F.L.L., et al. (2021). Prolonged SARS-  
791 CoV-2 Positivity in Immunocompetent Patients: Virus Isolation, Genomic Integrity, and  
792 Transmission Risk. *Microbiol. Spectr.* 9, e0085521. 10.1128/Spectrum.00855-21.
- 793 24. Murata, T., Sakurai, A., Suzuki, M., Komoto, S., Ide, T., Ishihara, T., and Doi, Y. Shedding  
794 of Viable Virus in Asymptomatic SARS-CoV-2 Carriers. *mSphere* 6, e00019-21.  
795 10.1128/mSphere.00019-21.
- 796 25. Owusu, D., Pomeroy, M.A., Lewis, N.M., Wadhwa, A., Yousaf, A.R., Whitaker, B.,  
797 Dietrich, E., Hall, A.J., Chu, V., Thornburg, N., et al. (2021). Persistent SARS-CoV-2 RNA  
798 Shedding Without Evidence of Infectiousness: A Cohort Study of Individuals With COVID-  
799 19. *J. Infect. Dis.* 224, 1362–1371. 10.1093/infdis/jiab107.
- 800 26. Heyer, A., Günther, T., Robitaille, A., Lütgehetmann, M., Addo, M.M., Jarczак, D., Kluge,  
801 S., Aepfelbacher, M., Wiesch, J.S. zur, Fischer, N., et al. (2022). Remdesivir-induced  
802 emergence of SARS-CoV2 variants in patients with prolonged infection. *Cell Rep. Med.* 3.  
803 10.1016/j.xcrm.2022.100735.
- 804 27. Liu, W.-D., Chang, S.-Y., Wang, J.-T., Tsai, M.-J., Hung, C.-C., Hsu, C.-L., and Chang, S.-  
805 C. (2020). Prolonged virus shedding even after seroconversion in a patient with COVID-19.  
806 *J. Infect.* 81, 318–356. 10.1016/j.jinf.2020.03.063.
- 807 28. Widders, A., Broom, A., and Broom, J. (2020). SARS-CoV-2: The viral shedding vs  
808 infectivity dilemma. *Infect. Dis. Health* 25, 210–215. 10.1016/j.idh.2020.05.002.
- 809 29. Vibholm, L.K., Nielsen, S.S.F., Pahus, M.H., Frattari, G.S., Olesen, R., Andersen, R.,  
810 Monrad, I., Andersen, A.H.F., Thomsen, M.M., Konrad, C.V., et al. (2021). SARS-CoV-2  
811 persistence is associated with antigen-specific CD8 T-cell responses. *EBioMedicine* 64,  
812 103230. 10.1016/j.ebiom.2021.103230.
- 813 30. Drénou, B., Amiot, L., Setterblad, N., Taque, S., Guilloux, V., Charron, D., Fauchet, R., and  
814 Mooney, N. (2005). MHC class II signaling function is regulated during maturation of  
815 plasmacytoid dendritic cells. *J. Leukoc. Biol.* 77, 560–567. 10.1189/jlb.0704423.
- 816 31. Cervantes-Barragan, L., Züst, R., Weber, F., Spiegel, M., Lang, K.S., Akira, S., Thiel, V.,  
817 and Ludewig, B. (2006). Control of coronavirus infection through plasmacytoid dendritic-  
818 cell-derived type I interferon. *Blood* 109, 1131–1137. 10.1182/blood-2006-05-023770.
- 819 32. Severa, M., Diotti, R.A., Etna, M.P., Rizzo, F., Fiore, S., Ricci, D., Iannetta, M., Sinigaglia,  
820 A., Lodi, A., Mancini, N., et al. (2021). Differential plasmacytoid dendritic cell phenotype  
821 and type I Interferon response in asymptomatic and severe COVID-19 infection. *PLOS*  
822 *Pathog.* 17, e1009878. 10.1371/journal.ppat.1009878.

- 823 33. Jamieson, A.M., Pasman, L., Yu, S., Gamradt, P., Homer, R.J., Decker, T., and Medzhitov,  
824 R. (2013). Role of tissue protection in lethal respiratory viral-bacterial coinfection. *Science*  
825 *340*, 1230–1234. [10.1126/science.1233632](https://doi.org/10.1126/science.1233632).
- 826 34. Piotti, A., Novelli, D., Meessen, J.M.T.A., Ferlicca, D., Coppolecchia, S., Marino, A., Salati,  
827 G., Savioli, M., Grasselli, G., Bellani, G., et al. (2021). Endothelial damage in septic shock  
828 patients as evidenced by circulating syndecan-1, sphingosine-1-phosphate and soluble VE-  
829 cadherin: a substudy of ALBIOS. *Crit. Care* *25*, 113. [10.1186/s13054-021-03545-1](https://doi.org/10.1186/s13054-021-03545-1).
- 830 35. Chen, D., Tang, T.-X., Deng, H., Yang, X.-P., and Tang, Z.-H. (2021). Interleukin-7 Biology  
831 and Its Effects on Immune Cells: Mediator of Generation, Differentiation, Survival, and  
832 Homeostasis. *Front. Immunol.* *12*.
- 833 36. Antonia, A.L., Gibbs, K.D., Trahair, E.D., Pittman, K.J., Martin, A.T., Schott, B.H., Smith,  
834 J.S., Rajagopal, S., Thompson, J.W., Reinhardt, R.L., et al. (2019). Pathogen Evasion of  
835 Chemokine Response Through Suppression of CXCL10. *Front. Cell. Infect. Microbiol.* *9*.
- 836 37. Smith, N., Goncalves, P., Charbit, B., Grzelak, L., Beretta, M., Planchais, C., Bruel, T.,  
837 Rouilly, V., Bondet, V., Hadjadj, J., et al. (2021). Distinct systemic and mucosal immune  
838 responses during acute SARS-CoV-2 infection. *Nat. Immunol.* *22*, 1428–1439.  
839 [10.1038/s41590-021-01028-7](https://doi.org/10.1038/s41590-021-01028-7).
- 840 38. Cheemarla, N.R., Watkins, T.A., Mihaylova, V.T., Wang, B., Zhao, D., Wang, G., Landry,  
841 M.L., and Foxman, E.F. (2021). Dynamic innate immune response determines susceptibility  
842 to SARS-CoV-2 infection and early replication kinetics. *J. Exp. Med.* *218*, e20210583.  
843 [10.1084/jem.20210583](https://doi.org/10.1084/jem.20210583).
- 844 39. Hou, W., Kang, H.S., and Kim, B.S. (2009). Th17 cells enhance viral persistence and inhibit  
845 T cell cytotoxicity in a model of chronic virus infection. *J. Exp. Med.* *206*, 313–328.  
846 [10.1084/jem.20082030](https://doi.org/10.1084/jem.20082030).
- 847 40. Medzhitov, R., Schneider, D.S., and Soares, M.P. (2012). Disease Tolerance as a Defense  
848 Strategy. *Science* *335*, 936–941. [10.1126/science.1214935](https://doi.org/10.1126/science.1214935).
- 849 41. Martins, R., Carlos, A.R., Braza, F., Thompson, J.A., Bastos-Amador, P., Ramos, S., and  
850 Soares, M.P. (2019). Disease Tolerance as an Inherent Component of Immunity. *Annu. Rev.*  
851 *Immunol.* *37*, 405–437. [10.1146/annurev-immunol-042718-041739](https://doi.org/10.1146/annurev-immunol-042718-041739).
- 852 42. Islam, H., Chamberlain, T.C., Mui, A.L., and Little, J.P. (2021). Elevated Interleukin-10  
853 Levels in COVID-19: Potentiation of Pro-Inflammatory Responses or Impaired Anti-  
854 Inflammatory Action? *Front. Immunol.* *12*.
- 855 43. Lu, L., Zhang, H., Dauphars, D.J., and He, Y.-W. (2021). A Potential Role of Interleukin 10  
856 in COVID-19 Pathogenesis. *Trends Immunol.* *42*, 3–5. [10.1016/j.it.2020.10.012](https://doi.org/10.1016/j.it.2020.10.012).
- 857 44. Moseman, E.A., Wu, T., Torre, J.C. de la, Schwartzberg, P.L., and McGavern, D.B. (2017).  
858 Type I interferon suppresses neutralizing antiviral B cell responses by modulating CD8+ T  
859 cell differentiation. *J. Immunol.* *198*, 122.1-122.1.



- 860 45. Bardel, E., Doucet-Ladeveze, R., Mathieu, C., Harandi, A.M., Dubois, B., and Kaiserlian, D.  
861 (2016). Intradermal immunisation using the TLR3-ligand Poly (I:C) as adjuvant induces  
862 mucosal antibody responses and protects against genital HSV-2 infection. *NPJ Vaccines* 1,  
863 16010. [10.1038/npjvaccines.2016.10](https://doi.org/10.1038/npjvaccines.2016.10).
- 864 46. Garcia-Beltran, W.F., Lam, E.C., Astudillo, M.G., Yang, D., Miller, T.E., Feldman, J.,  
865 Hauser, B.M., Caradonna, T.M., Clayton, K.L., Nitido, A.D., et al. (2021). COVID-19-  
866 neutralizing antibodies predict disease severity and survival. *Cell* 184, 476-488.e11.  
867 [10.1016/j.cell.2020.12.015](https://doi.org/10.1016/j.cell.2020.12.015).
- 868 47. Krause, P.R., Fleming, T.R., Longini, I.M., Peto, R., Briand, S., Heymann, D.L., Beral, V.,  
869 Snape, M.D., Rees, H., Roper, A.-M., et al. (2021). SARS-CoV-2 Variants and Vaccines.  
870 *N. Engl. J. Med.* 385, 179–186. [10.1056/NEJMs2105280](https://doi.org/10.1056/NEJMs2105280).
- 871 48. Alvim, R.G.F., Lima, T.M., Rodrigues, D.A.S., Marsili, F.F., Bozza, V.B.T., Higa, L.M.,  
872 Monteiro, F.L., Abreu, D.P.B., Leitão, I.C., Carvalho, R.S., et al. (2022). From a  
873 recombinant key antigen to an accurate, affordable serological test: lessons learnt from  
874 COVID-19 for future pandemics. *Biochem. Eng. J.*, 108537. [10.1016/j.bej.2022.108537](https://doi.org/10.1016/j.bej.2022.108537).
- 875
- 876
- 877
- 878